Delving into the Latest Updates on Firebrick Pharma Ltd. with Synapse

概览

关联

5

项与 Firebrick Pharma Ltd. 相关的临床试验

Confirmatory Phase III study of Nasodine Nasal Spray (povidone-iodine 0.5%) as a symptomatic treatment for early stage common cold in the natural setting.

开始日期2022-05-03

申办/合作机构

Firebrick Pharma Ltd.

ACTRN12621000034831 / Completed早期临床1期

Virucidal pilot study of Nasodine® (povidone-iodine 0.5%) nasal spray in people in South Africa with COVID-19 and confirmed nasal shedding of SARS-CoV-2 virus.

开始日期2020-11-20

申办/合作机构

Firebrick Pharma Ltd.

[+1]

ACTRN12620000470998 / Withdrawn早期临床1期

Virucidal pilot study of Nasodine® Antiseptic Nasal Spray (povidone-iodine 0.5%) in people with COVID-19 and confirmed nasal shedding of SARS-CoV-2 virus.

开始日期2020-04-20

申办/合作机构

Firebrick Pharma Ltd.

100 项与 Firebrick Pharma Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Firebrick Pharma Ltd. 相关的专利（医药）

登录后查看更多信息

1

项与 Firebrick Pharma Ltd. 相关的文献（医药）

2024-03-01·Diabetes

Liver-Selective Imidazolopyrazine Mitochondrial Uncoupler SHD865 Reverses Adiposity and Glucose Intolerance in Mice

Article

作者: Olzomer, Ellen M ; Alexopoulos, Stephanie J ; Santos, Webster L ; Li, Catherine ; Li, Keyong ; Hargett, Stefan R ; Vancuylenburg, Calum S ; Byrne, Frances L ; Hoehn, Kyle L ; Turner, Nigel ; Santiago-Rivera, José A ; Chen, Sing-Young ; Harris, Thurl E ; Bayliss, Douglas A ; Wathier, Michel ; Shah, Divya P ; Lee, Brendan ; Cermak, Jennifer M ; Tucker, Simon P ; Philp, Ashleigh M ; Philp, Andrew ; Beretta, Martina ; Dai, Yumin

Article Highlights:

100 项与 Firebrick Pharma Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Firebrick Pharma Ltd. 相关的转化医学

登录后查看更多信息